Metabolic approach to weight loss.
Revolutionizing wellness with
personalized online care
Our Treatments
Important safety information
Important Safety Information
COMPOUNDED SEMAGLUTIDE is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:
27 kg/m² or greater (overweight or obesity)
Limitations of Use:
- Co-administration with other COMPOUNDED SEMAGLUTIDE-containing products or any GLP-1 receptor agonist is not recommended.
- The safety and efficacy of coadministration with other products for weight management have not been established.
COMPOUNDED SEMAGLUTIDE has not been studied in patients with a history of pancreatitis.
WARNING: RISK OF THYROID C-CELL TUMORS
- In rodents, semaglutide causes thyroid C-cell tumors in clinically relevant exposures. It is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
Semaglutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.
Do not take COMPOUNDED SEMAGLUTIDE if you:
- Have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Have been diagnosed with pancreatitis or have a history of pancreatitis.
- Are allergic to semaglutide or any other GLP-1 drug or any of its inactive ingredients.
Have a history of suicidal attempts or active suicidal ideation.
WARNINGS AND PRECAUTIONS:
- Acute Pancreatitis: Has occurred in clinical trials. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.
- Acute Gallbladder Disease: Gallbladder issues have been observed in clinical trials. Clinical follow-up is needed if cholelithiasis is suspected.
- Hypoglycemia: The use of insulin secretagogues or insulin may increase the risk of hypoglycemia, including severe cases. Adjust the dose of insulin secretagogues or insulin accordingly.
- Acute Kidney Injury: Monitor renal function when starting or escalating doses in patients reporting severe gastrointestinal side effects.
- Hypersensitivity Reactions: Anaphylaxis and angioedema have been reported post-marketing. Discontinue if suspected.
- Pregnancy: Semaglutide may cause fetal harm. Discontinue immediately upon pregnancy recognition.
- Diabetic Retinopathy Complications: Monitor patients with a history of diabetic retinopathy.
- Heart Rate Increase: Monitor heart rate periodically.
Suicidal Behavior and Ideation: Monitor for signs of depression or suicidal thoughts. Discontinue if these symptoms develop.
Side Effects: Most common side effects (incidence ≥ 5%) include:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Fatigue
- Dyspepsia (indigestion)
- Dizziness
- Abdominal distension
- GERD (gastroesophageal reflux disease)
Headache
Drug Interactions: COMPOUNDED SEMAGLUTIDE delays gastric emptying, which may impact the absorption of oral medications. Use with caution.
Semaglutide
- Lowers A1C Levels
- Helps you feel full faster, longer
- Improves the way your body responds to sugars
- Semaglutide is not FDA-approved for weight loss, but may be prescribed if a provider deems it appropriate*
- 24/7 Provider & Nursing support
- Medications, syringes, alcohol swabs
- Weight monitoring via app
- Shipping delivered to your door
- Optional nutritional counseling
Semaglutide is typically administered as a once-weekly subcutaneous injection, meaning it is injected just under the skin, usually in the abdomen, thigh, or upper arm. It's important to rotate the injection site each week to avoid irritation. Always follow the dosing instructions provided by your healthcare provider, starting with a lower dose and gradually increasing based on your body's response. Be sure to use a clean needle for each injection and dispose of it safely. If you miss a dose, take it as soon as you remember, unless it's less than 48 hours before your next scheduled dose. Never double up on doses. For optimal results, use semaglutide in combination with a healthy diet and regular exercise
Common side effects of semaglutide may include nausea, vomiting, diarrhea, constipation, and abdominal pain, especially when starting treatment. Other possible side effects include fatigue, dizziness, and decreased appetite. In rare cases, semaglutide can cause more serious side effects like pancreatitis, gallbladder issues, or allergic reactions. If you experience severe abdominal pain, difficulty breathing, or swelling of the face or throat, seek medical attention immediately. Always consult your healthcare provider about any side effects or concerns you may have.
* This page has been medically reviewed
* Actual price to customer will depend on product and subscription plan purchase.
Important safety information
Important Safety Information
COMPOUNDED SEMAGLUTIDE is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:
27 kg/m² or greater (overweight or obesity)
Limitations of Use:
- Co-administration with other COMPOUNDED SEMAGLUTIDE-containing products or any GLP-1 receptor agonist is not recommended.
- The safety and efficacy of coadministration with other products for weight management have not been established.
COMPOUNDED SEMAGLUTIDE has not been studied in patients with a history of pancreatitis.
WARNING: RISK OF THYROID C-CELL TUMORS
- In rodents, semaglutide causes thyroid C-cell tumors in clinically relevant exposures. It is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
Semaglutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.
Do not take COMPOUNDED SEMAGLUTIDE if you:
- Have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Have been diagnosed with pancreatitis or have a history of pancreatitis.
- Are allergic to semaglutide or any other GLP-1 drug or any of its inactive ingredients.
Have a history of suicidal attempts or active suicidal ideation.
WARNINGS AND PRECAUTIONS:
- Acute Pancreatitis: Has occurred in clinical trials. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.
- Acute Gallbladder Disease: Gallbladder issues have been observed in clinical trials. Clinical follow-up is needed if cholelithiasis is suspected.
- Hypoglycemia: The use of insulin secretagogues or insulin may increase the risk of hypoglycemia, including severe cases. Adjust the dose of insulin secretagogues or insulin accordingly.
- Acute Kidney Injury: Monitor renal function when starting or escalating doses in patients reporting severe gastrointestinal side effects.
- Hypersensitivity Reactions: Anaphylaxis and angioedema have been reported post-marketing. Discontinue if suspected.
- Pregnancy: Semaglutide may cause fetal harm. Discontinue immediately upon pregnancy recognition.
- Diabetic Retinopathy Complications: Monitor patients with a history of diabetic retinopathy.
- Heart Rate Increase: Monitor heart rate periodically.
Suicidal Behavior and Ideation: Monitor for signs of depression or suicidal thoughts. Discontinue if these symptoms develop.
Side Effects: Most common side effects (incidence ≥ 5%) include:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Fatigue
- Dyspepsia (indigestion)
- Dizziness
- Abdominal distension
- GERD (gastroesophageal reflux disease)
Headache
Drug Interactions: COMPOUNDED SEMAGLUTIDE delays gastric emptying, which may impact the absorption of oral medications. Use with caution.
Important Safety Information
Important Safety Information
Tirzepatide is a dual GIP/GLP-1 receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:
27 kg/m² or greater (overweight or obesity)
Limitations of Use:
- Co-administration with other GIP/GLP-1 receptor agonists or any similar compounds is not recommended.
- The safety and efficacy of tirzepatide for weight management have not been established in combination with other products.
- Tirzepatide has not been studied in patients with a history of pancreatitis.
WARNING: RISK OF THYROID C-CELL TUMORS
- In animal studies, tirzepatide has caused thyroid C-cell tumors at clinically relevant exposures. It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. The relevance of these findings to humans remains uncertain.
- Tirzepatide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients on the potential risk of MTC and the symptoms of thyroid tumors.
Do not take tirzepatide if you:
- Have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
- Have been diagnosed with pancreatitis or have a history of pancreatitis.
- Are allergic to tirzepatide or any of its inactive ingredients.
- Have a history of suicidal attempts or active suicidal ideation.
WARNINGS AND PRECAUTIONS
- Acute Pancreatitis: Discontinue tirzepatide promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.
- Acute Gallbladder Disease: Gallbladder disease has been observed in clinical trials. Clinical follow-up and further studies are indicated if gallbladder issues are suspected.
- Hypoglycemia: Concomitant use with insulin or insulin secretagogues may increase the risk of hypoglycemia. Dose adjustments of insulin or insulin secretagogues may be necessary.
- Acute Kidney Injury: Monitor renal function when initiating or increasing doses in patients reporting severe gastrointestinal side effects.
- Hypersensitivity Reactions: Discontinue tirzepatide if hypersensitivity reactions such as anaphylaxis or angioedema occur and seek medical attention.
- Pregnancy: Tirzepatide may cause fetal harm. Discontinue the medication immediately upon recognizing pregnancy.
- Diabetic Retinopathy Complications: Patients with a history of diabetic retinopathy should be monitored closely.
- Heart Rate Increase: Monitor heart rate periodically.
- Suicidal Behavior and Ideation: Monitor for symptoms of depression or suicidal thoughts and discontinue if these symptoms develop.
Side Effects Most common side effects (incidence ≥ 5%) include:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Fatigue
- Dyspepsia (indigestion)
- Dizziness
- Abdominal distension
- Gastroesophageal reflux disease (GERD)
- Headache
Drug Interactions Tirzepatide delays gastric emptying and may impact the absorption of oral medications. Use with caution.
Use in Specific Populations
- Pregnancy: May cause fetal harm. Discontinue tirzepatide as soon as pregnancy is detected.
- Females and Males of Reproductive Potential: Discontinue tirzepatide at least 2 months before a planned pregnancy due to its long half-life.
Reporting Adverse Reactions To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.
Tirzepatide
Lowers A1C Levels
Helps you feel full faster, longer
Helps the body remove excess sugar from the blood
- 24/7 Provider & Nursing support
- Medications, syringes, alcohol swabs
- Weight monitoring via app
- Shipping delivered to your door
- Optional nutritional counseling
Common side effects with Tirzepatide include:
Redness & itching at the injection site
Loss of appetite
Tiredness
Nausea
Upset stomach
Diarrhea, or constipation may occur
Important Safety Information
Important Safety Information
Tirzepatide is a dual GIP/GLP-1 receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:
27 kg/m² or greater (overweight or obesity)
Limitations of Use:
- Co-administration with other GIP/GLP-1 receptor agonists or any similar compounds is not recommended.
- The safety and efficacy of tirzepatide for weight management have not been established in combination with other products.
- Tirzepatide has not been studied in patients with a history of pancreatitis.
WARNING: RISK OF THYROID C-CELL TUMORS
- In animal studies, tirzepatide has caused thyroid C-cell tumors at clinically relevant exposures. It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. The relevance of these findings to humans remains uncertain.
- Tirzepatide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients on the potential risk of MTC and the symptoms of thyroid tumors.
Do not take tirzepatide if you:
- Have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
- Have been diagnosed with pancreatitis or have a history of pancreatitis.
- Are allergic to tirzepatide or any of its inactive ingredients.
- Have a history of suicidal attempts or active suicidal ideation.
WARNINGS AND PRECAUTIONS
- Acute Pancreatitis: Discontinue tirzepatide promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.
- Acute Gallbladder Disease: Gallbladder disease has been observed in clinical trials. Clinical follow-up and further studies are indicated if gallbladder issues are suspected.
- Hypoglycemia: Concomitant use with insulin or insulin secretagogues may increase the risk of hypoglycemia. Dose adjustments of insulin or insulin secretagogues may be necessary.
- Acute Kidney Injury: Monitor renal function when initiating or increasing doses in patients reporting severe gastrointestinal side effects.
- Hypersensitivity Reactions: Discontinue tirzepatide if hypersensitivity reactions such as anaphylaxis or angioedema occur and seek medical attention.
- Pregnancy: Tirzepatide may cause fetal harm. Discontinue the medication immediately upon recognizing pregnancy.
- Diabetic Retinopathy Complications: Patients with a history of diabetic retinopathy should be monitored closely.
- Heart Rate Increase: Monitor heart rate periodically.
- Suicidal Behavior and Ideation: Monitor for symptoms of depression or suicidal thoughts and discontinue if these symptoms develop.
Side Effects Most common side effects (incidence ≥ 5%) include:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Fatigue
- Dyspepsia (indigestion)
- Dizziness
- Abdominal distension
- Gastroesophageal reflux disease (GERD)
- Headache
Drug Interactions Tirzepatide delays gastric emptying and may impact the absorption of oral medications. Use with caution.
Use in Specific Populations
- Pregnancy: May cause fetal harm. Discontinue tirzepatide as soon as pregnancy is detected.
- Females and Males of Reproductive Potential: Discontinue tirzepatide at least 2 months before a planned pregnancy due to its long half-life.
Reporting Adverse Reactions To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.
Metformin®
The primary mechanism of metformin involves several actions within the body:
Decreased Glucose Production: Metformin reduces the amount of glucose produced by the liver. In people with type 2 diabetes, the liver often produces excess glucose, contributing to high blood sugar levels. By inhibiting this process, metformin helps lower fasting blood sugar levels.
Enhanced Insulin Sensitivity: Metformin improves the body's response to insulin, a hormone that helps cells absorb glucose from the bloodstream. In individuals with insulin resistance (a common feature of type 2 diabetes), cells do not respond well to insulin, leading to elevated blood sugar levels. Metformin enhances insulin sensitivity, allowing cells to utilize insulin more effectively.
Decreased Intestinal Glucose Absorption: Metformin reduces the absorption of glucose from the intestines after eating, leading to lower post-meal blood sugar levels.
Promotion of Weight Loss: Metformin can help some people with type 2 diabetes lose weight or prevent weight gain. It may contribute to a feeling of fullness and reduce food intake in some individuals.
Blood Sugar Control: Metformin is highly effective in lowering and controlling blood sugar levels, especially fasting blood sugar. By regulating glucose production and improving insulin sensitivity, it helps individuals with type 2 diabetes maintain stable blood sugar levels.
Weight Management: Metformin is associated with modest weight loss or prevention of weight gain in some individuals. This can be particularly beneficial for people with type 2 diabetes who are overweight or obese.
Cardiovascular Health: Some studies suggest that metformin may have cardiovascular benefits, such as improving lipid profiles and reducing the risk of heart-related complications in people with diabetes.
Lower Risk of Certain Health Complications: Properly managed blood sugar levels with metformin can lower the risk of diabetes-related complications, including kidney disease, nerve damage, and eye problems.
Polycystic Ovary Syndrome (PCOS) Management: Metformin is often used to manage insulin resistance in women with PCOS, helping regulate menstrual cycles and improve fertility.
While it is generally considered safe and effective, like any medication, it can cause side effects in some individuals. Common side effects of metformin include:
Gastrointestinal Distress: One of the most common side effects is gastrointestinal upset, including diarrhea, nausea, vomiting, and abdominal discomfort. These symptoms often occur at the beginning of treatment and may subside over time.
Loss of Appetite: Some individuals may experience a reduced appetite or feelings of fullness.
Taste Disturbances: Metformin can cause a metallic taste in the mouth or a lack of taste sensation.
Lactic Acidosis (Rare): Although rare, metformin can potentially lead to a serious condition called lactic acidosis, characterized by the buildup of lactic acid in the bloodstream. This is more common in individuals with kidney or liver problems. Symptoms include difficulty breathing, muscle pain, sluggishness, and in severe cases, a drop in body temperature and heart rate. Anyone experiencing these symptoms should seek immediate medical attention.
Vitamin B12 Deficiency: Long-term use of metformin has been associated with a decrease in vitamin B12 absorption, potentially leading to a deficiency. Regular monitoring of vitamin B12 levels and supplementation if necessary is recommended.
Low Blood Sugar (Hypoglycemia) (in combination with other diabetes medications): Taking metformin in combination with other medications for diabetes can increase the risk of low blood sugar. Symptoms include shakiness, dizziness, sweating, irritability, confusion, and in severe cases, loss of consciousness.
Skin Reactions: Some individuals may experience mild skin reactions such as redness or itching.
It's important for individuals taking metformin to be aware of these potential side effects. If any side effects are experienced, it is crucial to inform a healthcare provider. Additionally, metformin should be used with caution in individuals with kidney or liver problems, as these organs play a role in the elimination of the medication from the body. Regular monitoring and dosage adjustments are typically done under medical supervision.
What are GLP-1s?
GLP-1s, or Glucagon-Like Peptide-1 agonists, are a class of medications designed to help manage blood sugar levels. These drugs mimic the action of GLP-1, a natural hormone in the body that helps regulate blood sugar levels by stimulating insulin secretion, slowing down digestion, and reducing appetite.
By mimicking this hormone, GLP-1s help lower blood sugar levels after meals, leading to better glycemic control. Additionally, they have been found to promote weight loss and may have cardiovascular benefits. GLP-1s are typically administered via injection and have become an important therapeutic option for individuals striving to better manage their diabetes and improve their overall health
Important Safety Information
Important Safety Information
Tirzepatide is a dual GIP/GLP-1 receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:
27 kg/m² or greater (overweight or obesity)
Limitations of Use:
- Co-administration with other GIP/GLP-1 receptor agonists or any similar compounds is not recommended.
- The safety and efficacy of tirzepatide for weight management have not been established in combination with other products.
- Tirzepatide has not been studied in patients with a history of pancreatitis.
WARNING: RISK OF THYROID C-CELL TUMORS
- In animal studies, tirzepatide has caused thyroid C-cell tumors at clinically relevant exposures. It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. The relevance of these findings to humans remains uncertain.
- Tirzepatide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients on the potential risk of MTC and the symptoms of thyroid tumors.
Do not take tirzepatide if you:
- Have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
- Have been diagnosed with pancreatitis or have a history of pancreatitis.
- Are allergic to tirzepatide or any of its inactive ingredients.
- Have a history of suicidal attempts or active suicidal ideation.
WARNINGS AND PRECAUTIONS
- Acute Pancreatitis: Discontinue tirzepatide promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.
- Acute Gallbladder Disease: Gallbladder disease has been observed in clinical trials. Clinical follow-up and further studies are indicated if gallbladder issues are suspected.
- Hypoglycemia: Concomitant use with insulin or insulin secretagogues may increase the risk of hypoglycemia. Dose adjustments of insulin or insulin secretagogues may be necessary.
- Acute Kidney Injury: Monitor renal function when initiating or increasing doses in patients reporting severe gastrointestinal side effects.
- Hypersensitivity Reactions: Discontinue tirzepatide if hypersensitivity reactions such as anaphylaxis or angioedema occur and seek medical attention.
- Pregnancy: Tirzepatide may cause fetal harm. Discontinue the medication immediately upon recognizing pregnancy.
- Diabetic Retinopathy Complications: Patients with a history of diabetic retinopathy should be monitored closely.
- Heart Rate Increase: Monitor heart rate periodically.
- Suicidal Behavior and Ideation: Monitor for symptoms of depression or suicidal thoughts and discontinue if these symptoms develop.
Side Effects Most common side effects (incidence ≥ 5%) include:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Fatigue
- Dyspepsia (indigestion)
- Dizziness
- Abdominal distension
- Gastroesophageal reflux disease (GERD)
- Headache
Drug Interactions Tirzepatide delays gastric emptying and may impact the absorption of oral medications. Use with caution.
Use in Specific Populations
- Pregnancy: May cause fetal harm. Discontinue tirzepatide as soon as pregnancy is detected.
- Females and Males of Reproductive Potential: Discontinue tirzepatide at least 2 months before a planned pregnancy due to its long half-life.
Reporting Adverse Reactions To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.
Tirzepatide
Lowers A1C Levels
Helps you feel full faster, longer
Helps the body remove excess sugar from the blood
- 24/7 Provider & Nursing support
- Medications, syringes, alcohol swabs
- Weight monitoring via app
- Shipping delivered to your door
- Optional nutritional counseling
Common side effects with Tirzepatide include:
Redness & itching at the injection site
Loss of appetite
Tiredness
Nausea
Upset stomach
Diarrhea, or constipation may occur
Important Safety Information
Important Safety Information
Tirzepatide is a dual GIP/GLP-1 receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:
27 kg/m² or greater (overweight or obesity)
Limitations of Use:
- Co-administration with other GIP/GLP-1 receptor agonists or any similar compounds is not recommended.
- The safety and efficacy of tirzepatide for weight management have not been established in combination with other products.
- Tirzepatide has not been studied in patients with a history of pancreatitis.
WARNING: RISK OF THYROID C-CELL TUMORS
- In animal studies, tirzepatide has caused thyroid C-cell tumors at clinically relevant exposures. It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. The relevance of these findings to humans remains uncertain.
- Tirzepatide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients on the potential risk of MTC and the symptoms of thyroid tumors.
Do not take tirzepatide if you:
- Have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
- Have been diagnosed with pancreatitis or have a history of pancreatitis.
- Are allergic to tirzepatide or any of its inactive ingredients.
- Have a history of suicidal attempts or active suicidal ideation.
WARNINGS AND PRECAUTIONS
- Acute Pancreatitis: Discontinue tirzepatide promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.
- Acute Gallbladder Disease: Gallbladder disease has been observed in clinical trials. Clinical follow-up and further studies are indicated if gallbladder issues are suspected.
- Hypoglycemia: Concomitant use with insulin or insulin secretagogues may increase the risk of hypoglycemia. Dose adjustments of insulin or insulin secretagogues may be necessary.
- Acute Kidney Injury: Monitor renal function when initiating or increasing doses in patients reporting severe gastrointestinal side effects.
- Hypersensitivity Reactions: Discontinue tirzepatide if hypersensitivity reactions such as anaphylaxis or angioedema occur and seek medical attention.
- Pregnancy: Tirzepatide may cause fetal harm. Discontinue the medication immediately upon recognizing pregnancy.
- Diabetic Retinopathy Complications: Patients with a history of diabetic retinopathy should be monitored closely.
- Heart Rate Increase: Monitor heart rate periodically.
- Suicidal Behavior and Ideation: Monitor for symptoms of depression or suicidal thoughts and discontinue if these symptoms develop.
Side Effects Most common side effects (incidence ≥ 5%) include:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Fatigue
- Dyspepsia (indigestion)
- Dizziness
- Abdominal distension
- Gastroesophageal reflux disease (GERD)
- Headache
Drug Interactions Tirzepatide delays gastric emptying and may impact the absorption of oral medications. Use with caution.
Use in Specific Populations
- Pregnancy: May cause fetal harm. Discontinue tirzepatide as soon as pregnancy is detected.
- Females and Males of Reproductive Potential: Discontinue tirzepatide at least 2 months before a planned pregnancy due to its long half-life.
Reporting Adverse Reactions To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.
Important safety information
Important Safety Information
COMPOUNDED SEMAGLUTIDE is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:
27 kg/m² or greater (overweight or obesity)
Limitations of Use:
- Co-administration with other COMPOUNDED SEMAGLUTIDE-containing products or any GLP-1 receptor agonist is not recommended.
- The safety and efficacy of coadministration with other products for weight management have not been established.
COMPOUNDED SEMAGLUTIDE has not been studied in patients with a history of pancreatitis.
WARNING: RISK OF THYROID C-CELL TUMORS
- In rodents, semaglutide causes thyroid C-cell tumors in clinically relevant exposures. It is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
Semaglutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.
Do not take COMPOUNDED SEMAGLUTIDE if you:
- Have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Have been diagnosed with pancreatitis or have a history of pancreatitis.
- Are allergic to semaglutide or any other GLP-1 drug or any of its inactive ingredients.
Have a history of suicidal attempts or active suicidal ideation.
WARNINGS AND PRECAUTIONS:
- Acute Pancreatitis: Has occurred in clinical trials. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.
- Acute Gallbladder Disease: Gallbladder issues have been observed in clinical trials. Clinical follow-up is needed if cholelithiasis is suspected.
- Hypoglycemia: The use of insulin secretagogues or insulin may increase the risk of hypoglycemia, including severe cases. Adjust the dose of insulin secretagogues or insulin accordingly.
- Acute Kidney Injury: Monitor renal function when starting or escalating doses in patients reporting severe gastrointestinal side effects.
- Hypersensitivity Reactions: Anaphylaxis and angioedema have been reported post-marketing. Discontinue if suspected.
- Pregnancy: Semaglutide may cause fetal harm. Discontinue immediately upon pregnancy recognition.
- Diabetic Retinopathy Complications: Monitor patients with a history of diabetic retinopathy.
- Heart Rate Increase: Monitor heart rate periodically.
Suicidal Behavior and Ideation: Monitor for signs of depression or suicidal thoughts. Discontinue if these symptoms develop.
Side Effects: Most common side effects (incidence ≥ 5%) include:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Fatigue
- Dyspepsia (indigestion)
- Dizziness
- Abdominal distension
- GERD (gastroesophageal reflux disease)
Headache
Drug Interactions: COMPOUNDED SEMAGLUTIDE delays gastric emptying, which may impact the absorption of oral medications. Use with caution.
Semaglutide
- Lowers A1C Levels
- Helps you feel full faster, longer
- Improves the way your body responds to sugars
- Semaglutide is not FDA-approved for weight loss, but may be prescribed if a provider deems it appropriate*
- 24/7 Provider & Nursing support
- Medications, syringes, alcohol swabs
- Weight monitoring via app
- Shipping delivered to your door
- Optional nutritional counseling
Semaglutide is typically administered as a once-weekly subcutaneous injection, meaning it is injected just under the skin, usually in the abdomen, thigh, or upper arm. It's important to rotate the injection site each week to avoid irritation. Always follow the dosing instructions provided by your healthcare provider, starting with a lower dose and gradually increasing based on your body's response. Be sure to use a clean needle for each injection and dispose of it safely. If you miss a dose, take it as soon as you remember, unless it's less than 48 hours before your next scheduled dose. Never double up on doses. For optimal results, use semaglutide in combination with a healthy diet and regular exercise
Common side effects of semaglutide may include nausea, vomiting, diarrhea, constipation, and abdominal pain, especially when starting treatment. Other possible side effects include fatigue, dizziness, and decreased appetite. In rare cases, semaglutide can cause more serious side effects like pancreatitis, gallbladder issues, or allergic reactions. If you experience severe abdominal pain, difficulty breathing, or swelling of the face or throat, seek medical attention immediately. Always consult your healthcare provider about any side effects or concerns you may have.
* This page has been medically reviewed
* Actual price to customer will depend on product and subscription plan purchase.
Important safety information
Important Safety Information
COMPOUNDED SEMAGLUTIDE is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:
27 kg/m² or greater (overweight or obesity)
Limitations of Use:
- Co-administration with other COMPOUNDED SEMAGLUTIDE-containing products or any GLP-1 receptor agonist is not recommended.
- The safety and efficacy of coadministration with other products for weight management have not been established.
COMPOUNDED SEMAGLUTIDE has not been studied in patients with a history of pancreatitis.
WARNING: RISK OF THYROID C-CELL TUMORS
- In rodents, semaglutide causes thyroid C-cell tumors in clinically relevant exposures. It is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
Semaglutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.
Do not take COMPOUNDED SEMAGLUTIDE if you:
- Have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Have been diagnosed with pancreatitis or have a history of pancreatitis.
- Are allergic to semaglutide or any other GLP-1 drug or any of its inactive ingredients.
Have a history of suicidal attempts or active suicidal ideation.
WARNINGS AND PRECAUTIONS:
- Acute Pancreatitis: Has occurred in clinical trials. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.
- Acute Gallbladder Disease: Gallbladder issues have been observed in clinical trials. Clinical follow-up is needed if cholelithiasis is suspected.
- Hypoglycemia: The use of insulin secretagogues or insulin may increase the risk of hypoglycemia, including severe cases. Adjust the dose of insulin secretagogues or insulin accordingly.
- Acute Kidney Injury: Monitor renal function when starting or escalating doses in patients reporting severe gastrointestinal side effects.
- Hypersensitivity Reactions: Anaphylaxis and angioedema have been reported post-marketing. Discontinue if suspected.
- Pregnancy: Semaglutide may cause fetal harm. Discontinue immediately upon pregnancy recognition.
- Diabetic Retinopathy Complications: Monitor patients with a history of diabetic retinopathy.
- Heart Rate Increase: Monitor heart rate periodically.
Suicidal Behavior and Ideation: Monitor for signs of depression or suicidal thoughts. Discontinue if these symptoms develop.
Side Effects: Most common side effects (incidence ≥ 5%) include:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Fatigue
- Dyspepsia (indigestion)
- Dizziness
- Abdominal distension
- GERD (gastroesophageal reflux disease)
Headache
Drug Interactions: COMPOUNDED SEMAGLUTIDE delays gastric emptying, which may impact the absorption of oral medications. Use with caution.
How it works
We help you lose weight with revolutionary medication, concierge medical support, nutritional coach support, optional meal planning & more
Provide your health background and weight loss objectives to your Olliscript-affiliated provider.
Provide your health background and weight loss objectives to your Olliscript-affiliated provider. Provide your health background and weight loss objectives to your Olliscript-affiliated provider.
Real people, real success.
Emily, 42
Lost 25lbs
Tom, 50
Lost 45bs
David, 32
Lost 35lbs
Jenna, 37
Lost 40lbs
Rachel, 34
Lost 20 lbs
Emily, 42
Lost 25lbs
"After struggling with my weight for years, my doctor recommended semaglutide. I was hesitant at first, but within just a few weeks, I started noticing significant changes. My appetite decreased, and I found it much easier to stick to a healthy diet. I’ve lost 25 pounds over the last four months, and I feel more in control of my eating habits. I did experience some nausea initially, but it was manageable and went away after a couple of weeks. Overall, I’m thrilled with the results and feel healthier than I have in years."
Tom, 50
Lost 45bs
"When my doctor suggested tirzepatide for weight management, I didn’t expect the dramatic impact it would have. Not only have I lost 45 pounds in five months, but I’ve also noticed my energy levels improving and my blood sugar stabilizing. I had some mild nausea and fatigue in the beginning, but those faded after the first month. I’ve never felt more in control of my health, and I’m so glad I decided to start this medication."
David, 32
Lost 35lbs
Tirzepatide has completely transformed my health journey. I’ve been using it for four months and have lost 35 pounds. The biggest difference for me is how much easier it is to manage my cravings and portion sizes. I experienced some mild dizziness and fatigue during the first couple of weeks, but those side effects have mostly gone away. I’m feeling more confident, healthier, and excited about reaching my goals.
Jenna, 37
Lost 40lbs
"I’ve been on semaglutide for six months now, and it’s been life-changing. My cravings for sweets and snacks have reduced significantly, and I’ve lost about 40 pounds since starting the treatment. The side effects were mild for me—just a bit of nausea in the first couple of weeks, but nothing too disruptive. My doctor has been very supportive, and I feel confident that I’ll be able to keep the weight off long-term."
Rachel, 34
Lost 20 lbs
"Semaglutide has been a game changer for me. I’ve struggled with weight for years, and nothing seemed to work until this. I’m three months in and have lost 20 pounds. It’s not just about the weight—I feel like my relationship with food has changed. I no longer feel the constant urge to eat, and I’m able to make healthier choices without feeling deprived. The side effects, like some nausea and bloating, were mild and temporary. I wish I had started this sooner!"